Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto
Background: The incidence of central nervous system (CNS) metastases in breast cancer patients is rising and has become a major clinical challenge. Only few data are published concerning risk factors for the development of CNS metastases as a first site of metastatic disease in breast cancer patient...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2019
|
| In: |
Breast cancer research
Year: 2019, Volume: 21, Pages: 1-8 |
| ISSN: | 1465-542X |
| DOI: | 10.1186/s13058-019-1144-x |
| Online Access: | Verlag, Volltext: https://doi.org/10.1186/s13058-019-1144-x Verlag, Volltext: https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-019-1144-x 
|
| Author Notes: | Elena Laakmann, Isabell Witzel, Peter A. Fasching, Mahdi Rezai, Christian Schem, Christine Solbach, Hans Tesch, Peter Klare, Andreas Schneeweiss, Christoph Salat, Dirk-Michael Zahm, Jens-Uwe Blohmer, Barbara Ingold-Heppner, Jens Huober, Claus Hanusch, Christian Jackisch, Mattea Reinisch, Michael Untch, Gunter von Minckwitz, Valentina Nekljudova, Volkmar Müller and Sibylle Loibl |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1670469182 | ||
| 003 | DE-627 | ||
| 005 | 20230426082349.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190801s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13058-019-1144-x |2 doi | |
| 035 | |a (DE-627)1670469182 | ||
| 035 | |a (DE-599)KXP1670469182 | ||
| 035 | |a (OCoLC)1341235174 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Laakmann, Elena |e VerfasserIn |0 (DE-588)1047790629 |0 (DE-627)77921921X |0 (DE-576)401609685 |4 aut | |
| 245 | 1 | 0 | |a Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto |c Elena Laakmann, Isabell Witzel, Peter A. Fasching, Mahdi Rezai, Christian Schem, Christine Solbach, Hans Tesch, Peter Klare, Andreas Schneeweiss, Christoph Salat, Dirk-Michael Zahm, Jens-Uwe Blohmer, Barbara Ingold-Heppner, Jens Huober, Claus Hanusch, Christian Jackisch, Mattea Reinisch, Michael Untch, Gunter von Minckwitz, Valentina Nekljudova, Volkmar Müller and Sibylle Loibl |
| 264 | 1 | |c 2019 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 01.08.2019 | ||
| 500 | |a Published: 10 May 2019 | ||
| 520 | |a Background: The incidence of central nervous system (CNS) metastases in breast cancer patients is rising and has become a major clinical challenge. Only few data are published concerning risk factors for the development of CNS metastases as a first site of metastatic disease in breast cancer patients. Moreover, the incidence of CNS metastases after modern neoadjuvant treatment is not clear. - Methods: We analyzed clinical factors associated with the occurrence of CNS metastases as the first site of metastatic disease in breast cancer patients after neoadjuvant treatment in the trials GeparQuinto and GeparSixto (n = 3160) where patients received targeted treatment in addition to taxane and anthracycline-based chemotherapy. - Results: After a median follow-up of 61 months, 108 (3%) of a total of 3160 patients developed CNS metastases as the first site of recurrence and 411 (13%) patients had metastatic disease outside the CNS. Thirty-six patients (1%) developed both CNS metastases and other distant metastases as the first site of metastatic disease. Regarding subtypes of the primary tumor, 1% of luminal A-like (11/954), 2% of luminal B-like (7/381), 4% of HER2-positive (34/809), and 6% of triple-negative patients (56/1008) developed CNS metastases as the first site of metastatic disease. In multivariate analysis, risk factors for the development of CNS metastases were larger tumor size (cT3-4; HR 1.63, 95% CI 1.08-2.46, p = 0.021), node-positive disease (HR 2.57, 95% CI 1.64-4.04, p < 0.001), no pCR after neoadjuvant chemotherapy (HR 2.29, 95% CI 1.32-3.97, p = 0.003), and HER2-positive (HR 3.80, 95% CI 1.89-7.64, p < 0.001) or triple-negative subtype (HR 6.38, 95% CI 3.28-12.44, p < 0.001). - Conclusions: Especially patients with HER2-positive and triple-negative tumors are at risk of developing CNS metastases despite effective systemic treatment. A better understanding of the underlying mechanisms is required in order to develop potential preventive strategies. | ||
| 700 | 1 | |a Schneeweiss, Andreas |d 1961- |e VerfasserIn |0 (DE-588)109972554 |0 (DE-627)632849630 |0 (DE-576)327251859 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Breast cancer research |d London : BioMed Central, 1999 |g 21(2019), Artikel-ID 60, Seite 1-8 |h Online-Ressource |w (DE-627)326645950 |w (DE-600)2041618-0 |w (DE-576)27922463X |x 1465-542X |7 nnas |a Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto |
| 773 | 1 | 8 | |g volume:21 |g year:2019 |g elocationid:60 |g pages:1-8 |g extent:8 |a Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto |
| 856 | 4 | 0 | |u https://doi.org/10.1186/s13058-019-1144-x |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-019-1144-x |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190801 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 109972554 |a Schneeweiss, Andreas |m 109972554:Schneeweiss, Andreas |d 910000 |d 910400 |e 910000PS109972554 |e 910400PS109972554 |k 0/910000/ |k 1/910000/910400/ |p 9 | ||
| 999 | |a KXP-PPN1670469182 |e 3502547637 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"8 S."}],"name":{"displayForm":["Elena Laakmann, Isabell Witzel, Peter A. Fasching, Mahdi Rezai, Christian Schem, Christine Solbach, Hans Tesch, Peter Klare, Andreas Schneeweiss, Christoph Salat, Dirk-Michael Zahm, Jens-Uwe Blohmer, Barbara Ingold-Heppner, Jens Huober, Claus Hanusch, Christian Jackisch, Mattea Reinisch, Michael Untch, Gunter von Minckwitz, Valentina Nekljudova, Volkmar Müller and Sibylle Loibl"]},"title":[{"title":"Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto","title_sort":"Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto"}],"recId":"1670469182","relHost":[{"type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["1.1999 -"],"note":["Gesehen am 29.12.2016"],"id":{"issn":["1465-542X"],"eki":["326645950"],"zdb":["2041618-0"]},"recId":"326645950","disp":"Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixtoBreast cancer research","title":[{"title_sort":"Breast cancer research","title":"Breast cancer research"}],"physDesc":[{"extent":"Online-Ressource"}],"part":{"extent":"8","pages":"1-8","text":"21(2019), Artikel-ID 60, Seite 1-8","volume":"21","year":"2019"},"language":["eng"],"origin":[{"dateIssuedKey":"1999","publisherPlace":"London","dateIssuedDisp":"1999-","publisher":"BioMed Central"}]}],"id":{"eki":["1670469182"],"doi":["10.1186/s13058-019-1144-x"]},"origin":[{"dateIssuedKey":"2019","dateIssuedDisp":"2019"}],"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 01.08.2019","Published: 10 May 2019"],"person":[{"given":"Elena","display":"Laakmann, Elena","family":"Laakmann","roleDisplay":"VerfasserIn","role":"aut"},{"display":"Schneeweiss, Andreas","given":"Andreas","role":"aut","roleDisplay":"VerfasserIn","family":"Schneeweiss"}]} | ||
| SRT | |a LAAKMANNELDEVELOPMEN2019 | ||